Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + platinum-based doublet chemotherapy
- Development stage
- Preclinical
- Lead developer
- 3D Medicines
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
Envafolimab + platinum-based doublet chemotherapy is a combination regimen under investigation for the treatment of various advanced solid tumors, particularly lung and gynecological cancers. **Envafolimab** is a subcutaneous, humanized single-domain anti–PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and PD-1, reducing cancer-mediated immune suppression. Platinum-based doublet chemotherapy refers to a regimen with a platinum compound (typically cisplatin, carboplatin, or nedaplatin) combined with a third-generation cytotoxic agent, such as etoposide, gemcitabine, paclitaxel, docetaxel, vinorelbine, or pemetrexed. This combination aims to harness the cytotoxic effect of chemotherapy and enhance antitumor immune responses via checkpoint inhibition. The combination has shown preliminary antitumor activity and manageable tolerability in small cell lung cancer and is being explored in other malignancies[5][6][2].
- Brand names
- Enweida
- Other names
- envafolimab + platinum-based doublet chemotherapyenvafolimab + carboplatin and etoposideenvafolimab plus platinum-based chemotherapy
02
Targets
TOP2A (DNA topoisomerase II)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on envafolimab + platinum-based doublet chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + platinum-based doublet chemotherapy.